Diverse human self-proteins

Diverse human self-proteins represent the collective array of endogenous polypeptides encoded by the human genome. These proteins are fundamental to cellular structure and function, and their recognition by the immune system is strictly regulated to maintain self-tolerance (Source: Janeway's Immunobiology, 9th Edition). Pathologically, the loss of tolerance to specific self-proteins, known as autoantigens, is the hallmark of autoimmune disorders where the immune system mounts a response against the body's own tissues (Source: NIH - National Institute of Allergy and Infectious Diseases). In pharmacology, while not a single target, this group is significant in the context of Intravenous Immunoglobulin (IVIG) therapy, which contains a broad spectrum of antibodies that can neutralize autoantibodies or modulate immune cells (Source: StatPearls - Intravenous Immunoglobulin). Additionally, the identification of specific self-proteins that are aberrantly expressed in tumors, known as tumor-associated antigens, is a primary focus for developing targeted immunotherapies like CAR-T cells. Due to its lack of specificity and its definition as a broad biological category rather than a discrete molecule, 'Diverse human self-proteins' is considered an incorrect designation for a specific therapeutic target.

Other names

Self-antigensAutoantigensEndogenous proteinsHost proteinsSelf-peptides

Therapeutic intervention typically involves the induction of immune tolerance, the neutralization of autoantibodies, or the suppression of immune responses directed against endogenous proteins.